Cargando…

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach

Obesity is a complex disease characterized by excessive fat accumulation which is caused by genetic, environmental and other factors. In recent years, there has been an increase in the morbidity, disability rate,and mortality due to obesity, making it great threat to people’s health and lives, and i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jing-Yue, Wang, Quan-Wei, Yang, Xin-Yu, Yang, Wei, Li, Dong-Rui, Jin, Jing-Yu, Zhang, Hui-Cong, Zhang, Xian-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945324/ https://www.ncbi.nlm.nih.gov/pubmed/36843578 http://dx.doi.org/10.3389/fendo.2023.1085799

Ejemplares similares

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials
por: Hu, Weiting, et al.
Publicado: (2022)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis
por: Wei, Jinjing, et al.
Publicado: (2022)

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
por: Du, Haiyang, et al.
Publicado: (2022)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
por: Gallwitz, Baptist
Publicado: (2022)

Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis
por: Wei, Jinjing, et al.
Publicado: (2022)

Impact of GLP-1 receptor agonist versus omega-3 fatty acids supplement on obesity-induced alterations of mitochondrial respiration
por: Jansen, Kirsten M., et al.
Publicado: (2023)

Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison
por: Jung, Han Na, et al.
Publicado: (2022)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?
por: Meng, Zhuqing, et al.
Publicado: (2023)

Gut Microbial Signatures for Glycemic Responses of GLP-1 Receptor Agonists in Type 2 Diabetic Patients: A Pilot Study
por: Tsai, Chih-Yiu, et al.
Publicado: (2022)

A Combination of Glucagon-Like Peptide-1 Receptor Agonist and Dietary Intervention Could Be a Promising Approach for Obesity Treatment
por: Lee, Chooi Yeng
Publicado: (2021)

GLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH
por: Li, Qiu-Xuan, et al.
Publicado: (2021)

Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
por: Cignarelli, Angelo, et al.
Publicado: (2022)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
por: Meier, Juris J., et al.
Publicado: (2021)

Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes
por: Tanday, Neil, et al.
Publicado: (2021)

GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?
por: Brunton, S
Publicado: (2014)

The GLP-1 Receptor Agonist Exenatide Ameliorates Bone Composition and Tissue Material Properties in High Fat Fed Diabetic Mice
por: Mansur, Sity Aishah, et al.
Publicado: (2019)

Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis
por: Ma, Hong, et al.
Publicado: (2023)

Circadian secretion rhythm of GLP-1 and its influencing factors
por: Liu, Chuanfeng, et al.
Publicado: (2022)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff, Lisa M, et al.
Publicado: (2010)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A Danish nationwide cohort study
por: Al-Mashhadi, Zheer Kejlberg, et al.
Publicado: (2022)

Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Zhu, Yuan, et al.
Publicado: (2021)

Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database
por: Liu, Lulu, et al.
Publicado: (2022)

SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study
por: Al-Mashhadi, Zheer Kejlberg, et al.
Publicado: (2022)

GLP-1 based therapeutics: simultaneously combating T2DM and obesity
por: Heppner, Kristy M., et al.
Publicado: (2015)

Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes
por: Di Dalmazi, Giulia, et al.
Publicado: (2022)

The role of lacteal integrity and junction transformation in obesity: A promising therapeutic target?
por: Xia, Qingsong, et al.
Publicado: (2022)

GLP-1 receptor agonist as a modulator of innate immunity
por: Chen, Jun, et al.
Publicado: (2022)

GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder
por: Panfili, Eleonora, et al.
Publicado: (2023)

Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
por: Stenlid, Rasmus, et al.
Publicado: (2023)

Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma
por: Wang, Wei-Ming, et al.
Publicado: (2022)

Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence
por: Muller, Dion R. P., et al.
Publicado: (2023)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
por: Hope, David C. D., et al.
Publicado: (2021)

Editorial: Incretin agonists in the treatment of obesity
por: Sun, Xiaodong, et al.
Publicado: (2023)

A potentially serious adverse effect of GLP-1 receptor agonists
por: Lu, Jinmiao, et al.
Publicado: (2023)

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
por: Madsen, Mette Simone Aae, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rip1a7blg337v54ed4so8g3pv4